ApicHope(SZ:300723) Bei Jing Shang Bao·2025-12-22 09:06Core Viewpoint - The company Yipinhong (300723) is set to receive a 9.07% stake in Arthrosi from its controlling shareholder, Guangdong Guangrun Group, to support its ongoing research and development efforts, coinciding with a significant acquisition deal involving Arthrosi and Sobi USA valued at approximately $9.5 billion in upfront payments and potential milestone payments [1][2]. Group 1 - The controlling shareholder will transfer its 9.07% stake in Arthrosi to the company without any conditions, based on the net proceeds from the E-round investment [1][2]. - Arthrosi is in the process of signing an acquisition agreement with Sobi USA, which includes an upfront payment of $9.5 billion (approximately 67.13 billion RMB) and up to $5.5 billion (approximately 38.87 billion RMB) in milestone payments [1]. - The E-round post-investment valuation of Arthrosi is reported to be $383 million [2]. Group 2 - The controlling shareholder expressed strong confidence in the acquisition of Arthrosi and the market potential for the gout innovation drug, AR882, in the Greater China region [2]. - The transfer of the stake is aimed at enhancing the company's innovation capabilities and fostering the development of more innovative drugs to benefit patients [2]. - The move is expected to bolster investor confidence in the company's ongoing and future research initiatives [2].